title: Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.
abstract: Overall five-year survival for patients with stage-II colon cancer averages 75% after surgery alone. However, some of these patients have poorer outcomes, similar to patients with stage-III disease. The proposed use of the Oncotype DX assay is to improve risk stratification for recurrence in stage-II colon cancer.
authors.affiliation: Kaiser Permanente Center for Health Research.
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Webber
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Lin
authors.lastname: Evelyn P Whitlock